The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma.
Gilead’s treatment will be funded through the Cancer Drugs Fund for adults with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, two aggressive subtypes of non-Hodgkin lymphoma.
